This is the authors' abstract. We don't add key points for this paper.
Casitas B-lineage lymphoma-b (Cbl-b), an E3 ubiquitin ligase, is a novel rising cancer immunotherapy target negatively regulating T cell response, yet the effects of its pharmacological inhibition on T cell activation remain unexplored. Here, we present a systematic pharmacological analysis of Cbl-b inhibition in T cells using a selective small-molecule Cbl-b inhibitor (Cbl-bi) which targets Cbl-b directly. Cbl-bi potentiates T-cell receptor (TCR) signaling in both Jurkat and primary murine T cells, as evidenced by increased phosphorylation of phospholipase C gamma 1 (PLCγ1) and extracellular signal-regulated kinase (Erk) and elevated interleukin-2 production following anti-CD3/CD28 stimulation. Transcriptomic profiling of Cbl-b-inhibited T cells revealed a pronounced activation and inflammatory signature, with enrichment of nuclear factor kB (NF-κB), mitogen-activated protein kinase (MAPK), and Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways. Pharmacological interrogation of downstream signaling demonstrated that MAPK pathway activity is essential for the enhanced activation conferred by Cbl-b inhibition. Moreover, co-inhibition of autophagy or hematopoietic progenitor kinase 1 (HPK1) synergistically amplified the pro-activation effect of Cbl-b inhibition. Collectively, these findings provide mechanistic insight into Cbl-b's immunosuppressive role and identify rational combination strategies targeting Cbl-b, autophagy, or HPK1 to robustly potentiate T cell function for immunotherapy of cancer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: